carvedilol has been researched along with Heart Diseases in 22 studies
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized, single-blind, placebo-controlled study, 91 women with recently diagnosed breast cancer undergoing ANT therapy were randomly assigned to groups treated with either carvedilol (n = 46) or placebo (n = 45)." | 9.24 | Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity. ( Baghyari, S; Esmaili, K; Janbabai, G; Nabati, M; Yazdani, J, 2017) |
| "In an open prospective 16-week study we carried out assessment of clinical efficacy, vaso- and cardioprotective properties of nonselective alpha and beta-adrenoblocker carvedilol used as monotherapy and in combination with nifedipine or as combination of these drugs with metformin and simvastatin." | 6.74 | [Provision of complex cardioprotection with the help of carvedilol in 1-2 degree arterial hypertension combined with metabolic syndrome]. ( Eliseeva, IV; Gusakovskaia, LI; Matrosova, IB; Oleĭnikov, VE; Tomashevskaia, IuA, 2009) |
| "Carvedilol was administered intraperitoneally to 8 week-old TO2 hamsters for 21 weeks at a dose of 11 mg/kg/day." | 5.33 | Carvedilol prevents myocardial fibrosis in hamsters. ( Ishii, T; Nanjo, S; Togane, Y; Yamazaki, J; Yoshikawa, K, 2006) |
| "In this randomized, single-blind, placebo-controlled study, 91 women with recently diagnosed breast cancer undergoing ANT therapy were randomly assigned to groups treated with either carvedilol (n = 46) or placebo (n = 45)." | 5.24 | Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity. ( Baghyari, S; Esmaili, K; Janbabai, G; Nabati, M; Yazdani, J, 2017) |
| "This prospective post-marketing drug use survey was conducted to assess the safety and efficacy of the β-adrenergic receptor antagonist (β-blocker) Artist® Tablets (carvedilol) in patients with hypertension in Japan." | 3.77 | Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey. ( Hiramatsu, K; Iizuka, T; Komiya, M; Matsumoto, T; Mori, Y; Nishikawa, Y; Zenimura, N, 2011) |
| "In an open prospective 16-week study we carried out assessment of clinical efficacy, vaso- and cardioprotective properties of nonselective alpha and beta-adrenoblocker carvedilol used as monotherapy and in combination with nifedipine or as combination of these drugs with metformin and simvastatin." | 2.74 | [Provision of complex cardioprotection with the help of carvedilol in 1-2 degree arterial hypertension combined with metabolic syndrome]. ( Eliseeva, IV; Gusakovskaia, LI; Matrosova, IB; Oleĭnikov, VE; Tomashevskaia, IuA, 2009) |
| "Advances in cancer treatment have greatly improved survival rates of children with cancer." | 2.48 | Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. ( Franco, VI; Harake, D; Henkel, JM; Lipshultz, SE; Miller, TL, 2012) |
| "Carvedilol is a non-selective beta-blocker which, besides its neuroprotective and vasculoprotective properties, has cardioprotective and antioxidant effects." | 2.44 | Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). ( Cabral, A; Gonçalves, L; Machado, V; Monteiro, P; Providência, LA, 2008) |
| "However, the treatment of hypertension in older patients is often complicated by the presence of concomitant disorders." | 2.38 | Antihypertensive treatment with a dual-acting beta-blocker in the elderly. ( Lessem, JN; Weber, MA, 1993) |
| "Carvedilol acts as a biased ligand to promote β1AR coupling to a Gi-PI3K-Akt-nitric oxide synthase 3 (NOS3) cascade and induces robust β1AR-cGMP-PKG signal." | 1.62 | Carvedilol induces biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility. ( Barbagallo, F; Deng, B; Liu, Y; Reddy, GR; Shi, Q; Wang, Q; Wang, Y; Wei, W; West, TM; Xiang, YK; Xu, B, 2021) |
| "Hypertension is one of the dangerous health conditions prevalent in society, is a risk factor for several other diseases if left untreated and anti-hypertensives (AHs) are the approved drugs to treat it." | 1.56 | Network-based approach highlighting interplay among anti-hypertensives: target coding-genes: diseases. ( Sharma, R, 2020) |
| "Carvedilol treatment in the OVX animals: prevented weight gain and slight hypertrophy, restored the reduced positive inotropic responses to Ca(2+) and isoproterenol, prevented the reduction in SERCA2a expression, abolished the increase in superoxide anion production, normalized the increase in p22(phox) expression, and decreased serum angiotensin converting enzyme (ACE) activity." | 1.39 | Carvedilol prevents ovariectomy-induced myocardial contractile dysfunction in female rat. ( Fernandes, AA; Fiorim, J; Forechi, L; Lima, FL; Pavan, BM; Potratz, FF; Ribeiro, RF; Stefanon, I; Vassallo, DV, 2013) |
| "Carvedilol is a nonselective ss-adrenergic receptor antagonist that also blocks alpha1-adrenergic receptors and is a potent antioxidant." | 1.35 | Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart. ( Casamassimi, A; de Nigris, F; Fiorito, C; Napoli, C; Rienzo, M; Schiano, C, 2008) |
| "Carvedilol was administered intraperitoneally to 8 week-old TO2 hamsters for 21 weeks at a dose of 11 mg/kg/day." | 1.33 | Carvedilol prevents myocardial fibrosis in hamsters. ( Ishii, T; Nanjo, S; Togane, Y; Yamazaki, J; Yoshikawa, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Q | 1 |
| Wang, Y | 1 |
| West, TM | 1 |
| Liu, Y | 1 |
| Reddy, GR | 1 |
| Barbagallo, F | 1 |
| Xu, B | 1 |
| Shi, Q | 1 |
| Deng, B | 1 |
| Wei, W | 1 |
| Xiang, YK | 1 |
| Sharma, R | 1 |
| Roberts, MA | 1 |
| Darssan, D | 1 |
| Badve, SV | 1 |
| Carroll, RP | 1 |
| Fahim, MA | 1 |
| Haluska, BA | 1 |
| Hawley, CM | 1 |
| Isbel, NM | 1 |
| Marshall, MR | 1 |
| Pascoe, EM | 1 |
| Pedagogos, E | 1 |
| Pilmore, HL | 1 |
| Snelling, P | 1 |
| Stanton, T | 1 |
| Tan, KS | 1 |
| Tonkin, AM | 1 |
| Vergara, LA | 1 |
| Ierino, FL | 1 |
| Kheiri, B | 1 |
| Abdalla, A | 1 |
| Osman, M | 1 |
| Haykal, T | 1 |
| Chahine, A | 1 |
| Ahmed, S | 1 |
| Osman, K | 1 |
| Hassan, M | 1 |
| Bachuwa, G | 1 |
| Bhatt, DL | 1 |
| Bocchi, EA | 1 |
| Avila, MS | 1 |
| Ayub-Ferreira, SM | 1 |
| Barbosa, RR | 1 |
| Bourguignon, TB | 1 |
| Torres, LD | 1 |
| Arruda, LS | 1 |
| Jacques, TM | 1 |
| Serpa, RG | 1 |
| Calil, OA | 1 |
| Barbosa, LFM | 1 |
| Yadav, CH | 1 |
| Najmi, AK | 1 |
| Akhtar, M | 1 |
| Khanam, R | 1 |
| Nabati, M | 1 |
| Janbabai, G | 1 |
| Baghyari, S | 1 |
| Esmaili, K | 1 |
| Yazdani, J | 1 |
| Machado, V | 1 |
| Cabral, A | 1 |
| Monteiro, P | 1 |
| Gonçalves, L | 1 |
| Providência, LA | 1 |
| Frishman, WH | 1 |
| Henderson, LS | 1 |
| Lukas, MA | 1 |
| Oleĭnikov, VE | 1 |
| Matrosova, IB | 1 |
| Eliseeva, IV | 1 |
| Tomashevskaia, IuA | 1 |
| Gusakovskaia, LI | 1 |
| Mori, Y | 1 |
| Nishikawa, Y | 1 |
| Iizuka, T | 1 |
| Zenimura, N | 1 |
| Matsumoto, T | 1 |
| Hiramatsu, K | 1 |
| Komiya, M | 1 |
| Harake, D | 1 |
| Franco, VI | 1 |
| Henkel, JM | 1 |
| Miller, TL | 1 |
| Lipshultz, SE | 1 |
| Ribeiro, RF | 1 |
| Potratz, FF | 1 |
| Pavan, BM | 1 |
| Forechi, L | 1 |
| Lima, FL | 1 |
| Fiorim, J | 1 |
| Fernandes, AA | 1 |
| Vassallo, DV | 1 |
| Stefanon, I | 1 |
| Voors, AA | 1 |
| van Gilst, WH | 1 |
| van Veldhuisen, DJ | 1 |
| Nanjo, S | 1 |
| Yamazaki, J | 1 |
| Yoshikawa, K | 1 |
| Ishii, T | 1 |
| Togane, Y | 1 |
| Mason, RP | 1 |
| Cockcroft, JR | 1 |
| de Nigris, F | 1 |
| Rienzo, M | 1 |
| Schiano, C | 1 |
| Fiorito, C | 1 |
| Casamassimi, A | 1 |
| Napoli, C | 1 |
| Lessem, JN | 1 |
| Weber, MA | 1 |
| SoRelle, R | 1 |
| Feuerstein, GZ | 1 |
| Paul, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)[NCT06005259] | Phase 4 | 264 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for carvedilol and Heart Diseases
| Article | Year |
|---|---|
Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.
Topics: Anthracyclines; Antioxidants; Cardiotoxicity; Carvedilol; Heart Diseases; Humans; Neoplasms | 2018 |
Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers.
Topics: Adrenergic beta-Antagonists; Adult; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Carvedilol; | 2018 |
Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin).
Topics: Adrenergic beta-Antagonists; Animals; Antibiotics, Antineoplastic; Carbazoles; Carvedilol; Doxorubic | 2008 |
Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carv | 2008 |
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
Topics: Adiponectin; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antibiotics, Ant | 2012 |
Targeting nitric oxide with drug therapy.
Topics: Adrenergic alpha-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzopyrans | 2006 |
Antihypertensive treatment with a dual-acting beta-blocker in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Heart Diseases; Humans; Hypertension; Pro | 1993 |
3 trials available for carvedilol and Heart Diseases
| Article | Year |
|---|---|
Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Carbazoles; Carvedilol; Female; Heart Diseases | 2017 |
Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Atrial Function, Left; Biomarkers; Breast | 2017 |
[Provision of complex cardioprotection with the help of carvedilol in 1-2 degree arterial hypertension combined with metabolic syndrome].
Topics: Adrenergic alpha-Antagonists; Adult; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Femal | 2009 |
12 other studies available for carvedilol and Heart Diseases
| Article | Year |
|---|---|
Carvedilol induces biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Cardiotonic Agents; Carvedilol; Cells, Cultured; C | 2021 |
Network-based approach highlighting interplay among anti-hypertensives: target coding-genes: diseases.
Topics: Antihypertensive Agents; Anxiety; Carvedilol; Drug Interactions; Gene Ontology; Heart Diseases; Huma | 2020 |
Aging, cardiotoxicity, and chemotherapy.
Topics: Adrenergic beta-Antagonists; Aging; Antineoplastic Agents; Carvedilol; Heart Diseases; Humans; Risk | 2019 |
Cardioprotective role of H₃R agonist imetit on isoproterenol-induced hemodynamic changes and oxidative stress in rats.
Topics: Adrenergic beta-Agonists; Animals; Antioxidants; Biomarkers; Blood Pressure; Body Height; Body Weigh | 2015 |
Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and ove | 2011 |
Carvedilol prevents ovariectomy-induced myocardial contractile dysfunction in female rat.
Topics: Adrenergic beta-Antagonists; Animals; Body Weight; Calcium; Carbazoles; Carvedilol; Female; Heart; H | 2013 |
[Beta-blocking drugs indicated in patients with heart failure].
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Heart Diseases; Heart Failure; | 2003 |
Carvedilol prevents myocardial fibrosis in hamsters.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cricetinae; Disease Models, Animal; Ec | 2006 |
Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Antibiotics, Antineoplastic; Benzopyrans | 2008 |
50th Annual scientific sessions of the American college of cardiology.
Topics: Adrenergic alpha-Antagonists; Angina Pectoris; Carbazoles; Carvedilol; Fibroblast Growth Factor 2; G | 2001 |
Apoptosis--new opportunities for novel therapeutics for heart diseases.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Apoptosis; Carbazoles; Carvedilol; DN | 2001 |
Apoptosis in cardiac disease: from basics to clinics--an editorial commentary.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Animals; Apoptosis; Carbazoles; Carve | 2001 |